Clinical trials: Other
Prevalence of Psychoactive Substances in Road Traffic, Psychoactive Substances in Accident Involved Drivers
Alcohol and Other Psychoactive Substances in Road Traffic - a Case-control Study
The main purpose of the study is to determine the accident risk when driving under the influence of psychoactive substances, including alcohol (DUI).
- Conditions
- Prevalence of Psychoactive Substances in Road Traffic, Psychoactive Substances in Accident Involved Drivers, Relative Risk Estimation of Accident Involvement for Impaired Drivers
- Trial name
- NCT00570518
- Where
- Finland
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
Schizophrenia, Psychiatric Disorders
Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
This trial is an open-label, multi-center, parallel-arm, single-dose trial in 2 groups: 1 group of subjects with normal renal function and 1 group of severely renally impaired subjects.
- Trial name
- NCT01289080
- Testing
- OPC-34712
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)
This is the sister study to the BMS "Cognitive Improvement with Aripiprazole (Abilify)" study (LSUHSC #H04-022). Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder both before and after a…
- Trial name
- NCT00211380
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Bipolar Disorder (BD), Schizophrenia Disorder
Physical Fitness, Physical Activity Level, Depression and Quality of Life in Bipolar and Schizophrenia Patients
Assessment of physical activity levels, physical fitness and quality of life of bipolar and schizophrenia patients is necessary to verify the effectiveness of treatments and care activities in Community Mental Health Centers…
- Trial name
- NCT07140042
- Testing
- Survey
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
Cannabis-Related Disorder, Cannabis Abuse
Implementing Screening for Cannabis and Other Drug Use Disorders in Primary Care: Impact on Diagnosis and Treatment
Our proposed evaluation study is designed to evaluate the impact of a recently completed stepped wedge cluster randomized trial, conducted at Kaiser Permanente Washington (KPWA), of an intervention to improve care and management…
- Conditions
- Cannabis-Related Disorder, Cannabis Abuse, Drug Abuse, Drug Use Disorders
- Trial name
- NCT06249542
- Testing
- Care Delivery Improvement Intervention
- Volunteers
- 363,936 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Mental Illness, Schizophrenia
Measuring Beliefs and Norms About Persons With Mental Illness
Survey experiment to estimate drivers of mental illness stigma
- Conditions
- Mental Illness, Schizophrenia, Bipolar Disorder, Depression
- Trial name
- NCT03656770
- Testing
- Survey questionnaire
- Where
- Uganda
- Volunteers
- 1,782 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Negative Symptom, Schizophrenia
Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia
Negative symptoms are one of the five-dimensional symptoms of patients with schizophrenia, and medications are not effective in treating negative symptoms.
- Conditions
- Negative Symptom, Schizophrenia, Amisulpride, Gut Microbiomes
- Trial name
- NCT04533724
- Testing
- Amisulpride
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Ego, Social Science
Self-Affirmation and Defensiveness to Health Messages for the Self vs. a Close Other
Background: Researchers want to learn about people s beliefs and values. They also want to learn about how people respond to information about cancer risk. They have created two short studies.
- Conditions
- Ego, Social Science, Cancer Prevention
- Trial name
- NCT02317380
- Where
- United States
- Volunteers
- 1,019 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Schizophrenia
A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone
The purposes of this study are to evaluate the effect of food on the pharmacokinetics of extended-release (ER) OROS paliperidone in healthy men, and to evaluate the effect of posture on the pharmacokinetics of ER OROS…
- Trial name
- NCT00838669
- Testing
- Extended release OROS paliperidone
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Skin Cancer
A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.
This is a pilot study of a community- based melanoma educational intervention in Bensonhurst, Brooklyn conducted in-person by a community-health worker employed by the Perlmutter Cancer Center.
- Trial name
- NCT07177638
- Testing
- Education Sessions to Improve Melanoma Knowledge and Awareness
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Conditions
- Schizophrenia, Psychotic Disorders, Psychosis
- Trial name
- PAFIP3_nc3Y (NCT03883204)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Preeclampsia, Severe Preeclampsia
First-trimester Prediction of Preeclampsia
Preeclampsia is a complication of pregnancy related to adverse maternal and neonatal outcomes, including fetal growth restriction and perinatal death.
- Conditions
- Preeclampsia, Severe Preeclampsia, Fetal Growth Restriction, Preterm Birth
- Trial name
- PREDICTION (NCT02189148)
- Where
- 4 sites in Canada
- Volunteers
- 7,554 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Atherosclerosis, Chronic Granulomatous Disease (CGD)
Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System
Background: Atherosclerosis, the arterial plaques or blockages that cause heart disease, develops in many people by the time they are in their mid-20s.
- Trial name
- NCT01063309
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit
Healthy
Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products
Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening.
- Trial name
- NCT00515944
- Testing
- Botulinum neurotoxin type A, free of complexing proteins
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Schizophrenia, Cannabis Abuse
Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia
Increasing evidence suggests modulating effects of cannabinoids on time of onset, severity, and outcome of schizophrenia. Efforts to discover the underlying pathomechanism have led to the assumption of gene x environment…
- Trial name
- NCT00376233
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Jena
Melanoma and Other Malignant Neoplasms of Skin
Modifying Young Adult Skin Cancer Risk and Protective Behaviors
Skin cancer is the most common cancer and can be deadly, debilitating, damaging, and disfiguring, yet is highly preventable. In 2014, the US Surgeon General made a call to action about the "major public health problem" of skin…
- Trial name
- UV4me2 (NCT03313492)
- Testing
- UV4.me2, UV4.me, E-Pamphlet
- Where
- 2 sites in United States
- Volunteers
- 1,746 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Psychotic Disorders, Cannabis Use Disorder
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis…
- Conditions
- Psychotic Disorders, Cannabis Use Disorder, Cannabis Dependence, Cannabis Use
- Trial name
- NCT05445180
- Testing
- Contingency management
- Where
- Canada
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia, Memory Disorders
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit…
- Conditions
- Schizophrenia, Memory Disorders, Cognition Disorders
- Trial name
- Atomoxetine (NCT00548327)
- Testing
- Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
Population aging is transforming the epidemiological landscape of the Asia-Pacific region at an unprecedented pace. By 2050, more than one quarter of the region's population will be aged over 60, with 36.7% of countries projected…
- Trial name
- NCT07917182
- Where
- China
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.